Home › Rheumatoid Arthritis › NCT07412704
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.
About the study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
What is being tested
- BMS-986528 (drug)
Sponsor: Bristol-Myers Squibb · Participants: 84 · Started: Sep 15, 2026
Contact the study team
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT07412704
Locations in the U.S.
| California | Local Institution - 0068, La Jolla (Not yet recruiting) Local Institution - 0070, Loma Linda (Not yet recruiting) Local Institution - 0069, Palo Alto (Not yet recruiting) |
| Colorado | Local Institution - 0050, Aurora (Not yet recruiting) Colorado Blood Cancer Institute, Denver |
| Florida | Local Institution - 0055, South Miami (Not yet recruiting) |
| New York | Local Institution - 0079, New York (Not yet recruiting) Local Institution - 0081, New York (Not yet recruiting) |
| Oregon | Local Institution - 0066, Portland (Not yet recruiting) |
| Pennsylvania | Local Institution - 0071, Philadelphia (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.